REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Lymphokine > Interferon InterferonInterferon patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190026 - Method of treatment using interferon-tau A composition for use in preparation of a medicament for treating a condition responsive to interferon therapy in a human subject is described. The composition includes interferon-tau in dosage form suitable for oral administration to the intestinal tract in an amount effective to produce an increase in the subject's blood ... 06/14/07 - 20070134199 - Formulation for a protein pharmaceutical without added human serum albumin (hsa) A composition for stabilization of protein agents in pharmaceuticals, the composition comprising the following two constituents: a) a surface active substance, in particular a non-ionic detergent (tenside), and b) a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or ... 05/03/07 - 20070098687 - Pharmaceutical composition containing interferon for the treatment of hpv infections Disclosed is a liquid pharmaceutical composition containing interferon for peroral administration, and the use thereof in the treatment of infections caused by human papilloma virus (HPV). ... 04/12/07 - 20070081975 - Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction. ... 03/01/07 - 20070048281 - Hcv combination therapy The invention relates to therapy of HCV infection, and more particularly to combination therapy of HCV infection. The combination therapy comprises combination of a HCV E1 vaccine and an antiviral agent. In one aspect, the antiviral agent may be an interferon. ... 02/15/07 - 20070036755 - Treatment with anti-vegf antibodies This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. ... 02/15/07 - 20070036754 - Treatment with anti-vegf antibodies This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. ... 02/15/07 - 20070036753 - Treatment with anti-vegf antibodies This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. ... 02/01/07 - 20070025964 - Hiv-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine The present invention discloses a method for treating HIV that includes administering β-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 ... 02/01/07 - 20070025963 - Methods for reduction of scar tissue formation A method for reducing formation of scar tissue by administering interferon-tau (IFNτ) to a patient is described. Methods for preventing excessive scar formation, such as keloid formation, and for reducing formation of adhesions by administering IFNτ are also described. Interferon-tau is administered systemically or locally in an amount effective to ... 01/04/07 - 20070003516 - Compounds, compositions and methods for the treatment of poxvirus infections The present application provides methods and compositions for combination therapy with antiviral compounds for the treatment of poxvirus infections, such as orthopox virus infections. In one embodiment, a method of treatment of a poxvirus infection is provided that comprises administering to a host in need thereof cidofovir, cyclic cidofovir, or ... 11/30/06 - 20060269516 - Interferon-igg fusion The present invention provides, inter alia, polypeptides for the treatment of various diseases such as HCV as well as methods of treatment and methods of making the polypeptides. ... 11/16/06 - 20060257364 - Materials and methods for inhibition of ige production The subject invention concerns novel methods and materials for treating patients afflicted with allergic conditions, such as allergic rhinitis, atopic dermatitis, bronchial asthma and food allergy. The method of the subject invention comprises administering interferon tau (IFNτ) or a chimeric IFN (ovine IFNτ (1-27)/human IFNαD (28-166)) to a person afflicted ... 11/16/06 - 20060257363 - Treatment using an interferon Methods of treatment using a high oral dose of an interferon are described. An interferon, such as interferon-alpha, interferon-beta, or interferon-tau, is administered to persons afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation. ... 11/09/06 - 20060251618 - Implantable device for continuous delivery of interferon An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 μg/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period ... 08/03/06 - 20060171921 - Glycosylated interferon This invention includes compositions comprising glycosylated human interferon-α derived from a chicken. ... 08/03/06 - 20060171920 - Reversible pegylated drugs Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG ... 07/27/06 - 20060165654 - Peptides and recombinant proteins mimicking interferons The present invention provides peptide and recombinant protein mimetics specifically representing the antiviral and antiproliferative activities of interferons with avoiding interferons' undesirable side effects during treatment of a variety of diseases. The basic embodiment of the present invention was to link together, through a short artificial spacer, two primary protein ... 06/01/06 - 20060115453 - Methods and compositions for treating cellular proliferative diseases The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders. ... 05/11/06 - 20060099174 - Interferon-alpha induced genes The present disclosure relates to identification of genes upregulated by interferon-α administration, in particular the human genes corresponding to the cDNA sequences in GenBank designated g4586459, g2342476, g3327161 and g4529886. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-α and ... 05/11/06 - 20060099173 - Topical skin care composition A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma. ... 05/04/06 - 20060093577 - Combination anti-viral compositions and methods of use The present disclosure relates generally to the use of castanospermine in combination with another therapeutic agent to treat or prevent infections caused by or associated with a virus of the Flaviviridae family, particularly infections caused by or associated with Hepatitis C virus (HCV), and to the use of such compounds ... 04/27/06 - 20060088502 - Drug for reducing side effects in ribavirin interferon combination therapy There is provided a drug for reducing side effects, anemia in particular, in combination therapy of chronic hepatitis C with ribavirin and interferon, which contains as the active ingredient at least one member selected from the group consisting of eicosapentaenoic acid (EPA) and pharmaceutically acceptable salts and esters thereof. ... 03/30/06 - 20060067913 - Hcv therapy A peptide which has at least 80% identity to a fragment of Domain A or B of the Hepreceptor of ezrin, is used in the treatment of viral hepatitis. ... 03/16/06 - 20060057105 - Methods of treating ocular inflammation and allergy The present specification discloses methods of treating ocular inflammation and ocular allergy through the administration of interferon inhibitors to a mammal, including a human, in need thereof. ... 03/16/06 - 20060057104 - Methods for stimulating tlr irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses The present invention provides methods for stimulating Toll-like receptors (TLR) to activate IRF (e.g., an IRF3) and signaling pathway, and thereby directing an antimicrobial activity. The present invention also provides methods for identifying agents that bind and/or stimulate TLR and mediate induction of an IRF3 pathway, thereby directing an antimicrobial ... 03/09/06 - 20060051320 - Stable pegylated interferon formulation The present invention relates to lyophilized formulations of pegylated interferon which are prepared using trehalose as a cryoprotectant. The formulations have a low moisture content, which helps stabilize the pegylated interferon during storage of the formulations at room temperature. In addition, methods for preparing these formulations are provided. ... 03/02/06 - 20060045869 - Absorption enhancers for drug administration A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via ... 03/02/06 - 20060045868 - Absorption enhancers for drug administration A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via ... 02/02/06 - 20060024270 - Compositions and methods for preventing or treating encephalitis with interferon Compositions and methods are provided for preventing or treating a human suffering from a meningitis, encephalitis, meningo-encephalitis or encephalomyelitis caused by an arbovirus, comprising parenterally administering to the human an effective amount of interferon. ... 01/26/06 - 20060018874 - Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the ... 12/29/05 - 20050287115 - Treatment of ocular lesions Methods for the treatment of ocular lesions, particularly diseases of the surface of the eye, selected from pterygium, pinguecula, ocular dysplasia, ocular neoplastic disorders including malignancy of the limbus and eyelids in humans and animals, neurotrophic keratitis, fibrosis of conjunctival drainage blebs in glaucoma and viral disorders of the eye ... 12/01/05 - 20050265968 - Method of treating il-10 deficiency A method for treating an IL-10 deficiency in a human subject is described, where a person having an IL-10 deficiency is identified and treated with interferon-tau (IFNτ) at a dose sufficient to increase the IL-10 level. ... 12/01/05 - 20050265967 - Interferon-alpha induced gene The present invention relates to identification of a gene upregulated by interferon-administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon- and other interferons which act at the ... 11/10/05 - 20050249702 - (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis c virus ns3/ns4a serine protease The present invention discloses the compound of Formula 3 as an inhibitor of HCV protease, as well as methods for preparing the compound. In another embodiment, the invention discloses pharmaceutical compositions comprising the compound as well as methods of using them to treat disorders associated with the HCV protease. ... 11/03/05 - 20050244373 - Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2′,5′-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-τ until a measurable increase in blood 2′,5′-oligoadenylate synthetase level, relative ... 10/13/05 - 20050226845 - Method of treatment using interferon-tau Methods of treating a disease or condition responsive to interleukin-10 therapy in a mammal are provided. In one form, a method includes orally administering a therapeutically effective amount of interferon tau to the mammal. In other forms of the invention, the method includes administering a second therapeutic agent to the ... 10/06/05 - 20050220762 - Modified human interferon polypeptides and their uses Modified human interferon polypeptides and uses thereof are provided. ... 09/15/05 - 20050201981 - Method of optimizing treatment with interferon-tau Improvements in a method of treating a human disease or condition responsive to continued and periodic interferon-tau administration in humans are provided, by adjusting the dose administered to the patient in accordance with the patient's serum IL-10 response. ... 09/15/05 - 20050201980 - Method for short-term and long-term drug dosimetry Methods for the treatment of interferon-response disorders by administration of an interferon alone or in combination with adjunctive therapy are described. The invention encompasses providing to a patient both a formulation of an interferon that is suitable for short-term administration and a formulation of an interferon associated with a sustained ... 09/08/05 - 20050196379 - Combination therapies with l-fmau for the treatment of hepatitis b virus infection L-FMAU administered in combination and/or alternation with FTC and in combination and/or alternation with an interferon, such as interferon alpha or interferon gamma provides superior therapy in humans against hepatitis B virus. ... 09/01/05 - 20050191275 - Method for short-term and long-term drug dosimetry Methods for the treatment of interferon-response disorders by administration of an interferon alone or in combination with adjunctive therapy are described. The invention encompasses providing to a patient both a formulation of an interferon that is suitable for short-term administration and a formulation of an interferon associated with a sustained ... 08/18/05 - 20050180953 - Induction method for cell differentiation The invention relates to the induction method for cell differentiation which consists in injecting peptide derivatives having the following general formula (I): and used as a differentiation-inducing factor. Said peptide derivatives are used for curing oncological diseases, in particular for stabilising melanoma growth, increasing the efficiency of melanoma immunotherapy and ... 08/11/05 - 20050175585 - Combination therapies using vitamin b12 and interferon for treatment of viral proliferative and inflammatory disesases Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compound in combination with an interferon compound. Vitamin B12 compounds are administered separately, simultaneously or in combination with interferon compounds to provide an enhanced therapeutic effect for treating viral, proliferative and ... 08/04/05 - 20050169885 - Recombinant super-compound interferon This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and, therefore, is useful in preventing and treating viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its ... 07/28/05 - 20050163751 - Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compounds in combination with anti-viral, anti-proliferative and anti-inflammatory compounds. Vitamin B12 compounds are administered separately, simultaneously or in combination with anti-viral, anti-proliferative and/or anti-inflammatory compounds to provide an enhanced therapeutic effect ... 07/07/05 - 20050147588 - Methods for treatment of obesity and for promotion of weight loss Methods for promoting weight loss and/or preventing weight gain, particularly excessive weight gain, in subjects carrying excess body weight are described. The methods involve administering interferon-tau to the subject. Also described are methods for reducing body weight or preventing weight gain in subjects at risk of developing or already suffering ... 06/30/05 - 20050142109 - Method of treatment using interferon-tau Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFNτ are described. More specifically, a method of up-regulating the IL-10 level in patients afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFNτ is described. ... 06/16/05 - 20050129659 - Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against hcv infections The present invention relates to anti-HCV dihaloacetamide compounds in synergistic combination with an interferon and/or ribavirin and pharmaceutical compositions thereof for inhibition of the replication of HCV virus. The present invention also relates to the use of the compositions to inhibit HCV replication and/or proliferation and to treat or prevent ... 06/02/05 - 20050118138 - Method of treatment using interferon-tau A method of preventing an increase in the blood level of IFN-γ in a subject at risk of an elevated IFN-γ blood level due to (i) administration of a therapeutic agent or (ii) a disease condition is described. The method includes administering interferon-tau (IFNτ) at a dosage sufficient to maintain ... 06/02/05 - 20050118137 - Method of treatment using interferon-tau A method of increasing IL-10/IFNγ ratio in subjects suffering from an autoimmune condition or a viral infection is described. IFNτ is administered in a dose sufficient to increase the IL-1010/IFN-γ blood ratio, to prevent on-set, to prevent progression, or to treat these conditions. ... ### FreshPatents.com Support |